Longeveron is focused on developing cellular therapy primarily for chronic aging-related diseases, and other life-threatening conditions, for which there is a clear unmet medical need.
Our mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community.
Hypoplastic Left Heart Syndrome (HLHS)
Research Program
(U.S.)
Phase 2a trial actively enrolling.
Alzheimer’s Disease
(U.S.)
Phase 2 trial enrolling.
Aging Frailty Phase 2b
(U.S. & Japan)
2b Single-Dose Trial Complete; data announced Q3 2021. Japan Ph2 initiates 4Q 2022
Acute Respiratory Distress
Syndrome (ARDS)
We sponsor a Treatment Registry Trial in The Bahamas under the approval and authority of the National Stem Cell Ethics Committee (NSCEC). Eligible participants for the Registry may receive Lomecel-B at their own expense at one of two private partner clinics in Nassau for NSCEC-approved indications: Frailty, mild cognitive impairment, Alzheimer’s Disease and related dementias, and osteoarthritis. Lomecel-B is not an approved product in The Bahamas or the United States, and is considered an investigational therapeutic. For more information about this program please contact us.
Click here to replay our KOL event, which was held on August 16, 2023, featuring Sunjay Kaushal, MD, PhD and Ram Kumar Subramanyan, MD, PhD, discussing the potential for Medicinal Signaling Cells (MSCs), such as those making up Longeveron’s Lomecel-B™ injection, to improve the outcome for Hypoplastic Left Heart Syndrome (HLHS) patients.
Click Here to Watch the Replay